Continued Development. In the event that Anthra reasonably determines at any time that the NDA for an indication for the Product is unlikely to be approved by the FDA, then it shall so notify Medeva, whereupon Anthra shall have no further obligation pursuant to this Article II to conduct any Development Activities with respect to such indication for the Product. Upon receipt of such notice, Medeva shall elect, in its sole discretion, either to terminate this Agreement with respect to such indication for the Product, or to continue (or contract for a third party to continue) such Development Activities at the sole expense of Medeva. Medeva shall notify Anthra of such election within ninety (90) days after the receipt of the notice referred to *** CONFIDENTIAL TREATMENT REQUESTED.
Continued Development. At Pfizer’s request and expense, Iterum shall continue on-going Development for a mutually agreed-upon period following termination of this Agreement, which period shall be at least [ * ] but not be less than [ * ] unless otherwise agreed to by the Parties. For avoidance of doubt, if Pfizer chooses not to continue a Clinical Trial initiated by Iterum, Iterum shall be solely responsible for the cost of winding down such trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.
Continued Development. At Pfizer’s request and expense, Licensee shall continue on-going Development for a mutually agreed-upon period following terminating of this Agreement, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if Pfizer chooses not to continue a Clinical Trial initiated by Licensee, Licensee shall be solely responsible for the cost of winding down such trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.
Continued Development. At Pfizer’s request, Licensee shall continue on-going Development of the Products for a mutually agreed-upon period following termination of this Agreement, which period shall not be less than three (3) months unless otherwise agreed to by the Parties; provided, however, that if Pfizer chooses not to continue a Clinical Trial initiated by Licensee or if, for the safety of any subject, any Clinical Trial with respect to a Product should not be continued, Licensee shall be solely responsible for the cost of winding down such trial, including any costs arising from compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.
Continued Development. Within thirty (30) days following the execution of this Agreement, Transgenomic shall create a bank account funded with the amount of One Hundred Fifty Thousand Dollars ($150,000), said account to be owned by Transgenomic, and which funds will be used by Power3, with prior agreement by Transgenomic, to fund Power3’s clinical validation activities of the Neurodegenerative Diagnostic Tests; provided that the availability of such funds to Power3 shall be governed by the terms and conditions set forth in the Disbursement Control Agreement attached hereto as Exhibit D. Clinical validation of the Neurodegenerative Diagnostic Tests shall be the responsibility of Power3 until such time, if any, as Transgenomic shall assume some or all of the future responsibility for clinical validation of the Neurodegenerative Diagnostic Tests pursuant to Section 8.2. Power3 shall use commercially reasonable efforts for said development and shall keep Transgenomic informed about its progress in regular reports. Power3 shall disclose to Transgenomic the available technical and clinical performance data of the then-current version of its tests on regular basis, but in no event less often than monthly.
Continued Development. In the event of successful completion of the Phase 1 study of the Covid Vaccine as described in the Project, and the Foundation has made all payments to Icosavax in accordance with the terms of the Grant Agreement, Icosavax will take reasonable steps to obtain additional funding for completing the activities necessary to further develop the Covid Vaccine beyond the Phase 1 study. Within [***] of the [***], Icosavax will have received or will have a [***] to further develop, manufacture, and/or distribute the Covid Vaccine. If Icosavax [***] and continues the development and commercialization of the Covid Vaccine, the following terms apply:
Continued Development. At ImmunoGen’s request and expense, Licensee shall continue on-going Development for a mutually agreed-upon period following terminating of this Agreement, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if ImmunoGen chooses not to continue a Clinical Trial initiated by Licensee, Licensee shall be solely responsible for the cost of winding down such trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.
Continued Development. In order to facilitate continued development of, and integration with, each Service API and Web Service by You and others, (a) You hereby grant to Mastercard, licensees of Mastercard Developers Materials, and users of each Service API and Web Service a limited non-exclusive, royalty-free, irrevocable, worldwide license under any patent claims arising from Your development of or otherwise owned or licensable by You and covering Licensed Implementations to use, make, have made, sell, offer to sell, and import the products, services, and solutions that implement a Service API or that integrate with a Web Service; and (b) You hereby grant to Mastercard a perpetual, irrevocable, nonexclusive, transferable, royalty-free, fully paid-up, worldwide license with the right to grant sublicenses to use and exploit in any manner and without any restrictions, any suggestions that You provide to Mastercard regarding a Service API, a Web Service, or the Mastercard Developers Materials, including suggestions for improvements and corrections. In addition, Mastercard is not obligated to maintain the confidentiality of any information made available by You to Mastercard under this Agreement.
Continued Development. At Pfizer’s request and expense, Licensee shall continue on-going Development for a mutually agreed-upon period following termination of this Agreement, which period shall not be less than [*****] unless otherwise agreed to by the Parties. For avoidance of doubt, [*****].
Continued Development. From the Effective Date until the Termination Date (as defined below) (the “Development Period”), Buyer shall use commercially reasonable efforts to develop the Pipeline Products substantially in accordance with the Pipeline Specifications. The parties shall agree in writing on a completion date (a “Completion Date”) for each Pipeline Product and a development budget for each such Pipeline Product. Such development budget shall include a schedule for payment of Allergan’s share of Buyer’s costs, as set forth in Section 1.1(c), below, and shall provide for a hold back of *** of the budgeted costs until development of said Pipeline Product is completed to Allergan’s reasonable satisfaction. Allergan understands and acknowledges that the development of any particular Pipeline Product in accordance with the Pipeline Specifications by the Completion Date may not be feasible and that Buyer may change such Pipeline Specifications or Completion Date with Allergan’s written consent, which shall not be unreasonably withheld. Buyer will not be in breach of its obligations hereunder if its reasonable commercial efforts are not sufficient to successfully complete the development of any particular Pipeline Product. Allergan agrees to use reasonable commercial efforts to assist Buyer in the continued development of Pipeline Products, including but not limited to, making its marketing staff reasonably available to Buyer for up to one day during any calendar month during the Development Period.
